Skip to main
BLCO
BLCO logo

BLCO Stock Forecast & Price Target

BLCO Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 8%
Buy 25%
Hold 58%
Sell 8%
Strong Sell 0%

Bulls say

Bausch & Lomb has raised its revenue guidance for 2025 to a range of $5,050-$5,150 million, indicating a projected growth rate of 5-7% on a constant currency basis, alongside an expected adjusted EBITDA increase to $860-$910 million. The company is experiencing strong growth in its premium intraocular lens offerings, with notable contributions from the enVista and LUX platforms, and its product MIEBO has reported an impressive 110-111% year-over-year prescription growth. Additionally, the firm has benefited from foreign exchange tailwinds contributing $25 million to its full-year revenue, supporting a robust financial outlook despite potential tariff impacts.

Bears say

Bausch & Lomb is experiencing challenges in maintaining its competitive edge in the ophthalmology market due to increased pricing pressure on products like XIIDRA, as well as limited pipeline development and investments made during its prior association with Bausch Health. The company faces significant risks, including macroeconomic factors that may impact elective procedures like cataract surgeries, fluctuations in emerging markets, and high leverage from the acquisition of Xiidra, all of which could adversely affect growth and investor confidence. Projected financial metrics indicate a projected adjusted EPS of $0.75 and high net debt of $13.25 per share, reflecting concerns around long-term profitability and growth sustainability.

BLCO has been analyzed by 12 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 25% recommend Buy, 58% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bausch + Lomb Corp (BLCO) Forecast

Analysts have given BLCO a Hold based on their latest research and market trends.

According to 12 analysts, BLCO has a Hold consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bausch + Lomb Corp (BLCO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.